Articles tagged with Melanoma
Researchers have uncovered key tumor-stroma interactions that drive drug resistance in melanoma leptomeningeal disease. The study identifies a potential therapeutic target by inhibiting SERPINA3-mediated signaling.
A new strategy for improving melanoma treatment involves targeting the communication between immune cells within the tumor. By neutralizing specific molecules, researchers found that CD8+ T cell activity against tumors increased while T regulatory cells' ability to inhibit the immune response decreased.
A research team from the University of Liège has discovered that inhibition of VARS enzyme can prevent therapeutic resistance in melanoma by resensitising tumours. This breakthrough offers new hope for patients with resistant melanoma, paving the way for treatment combinations and enhancing targeted therapy efficacy.
The first phase 1 trial of the bispecific antibody FS222 demonstrates promising antitumour activity, especially in patients with metastatic cutaneous melanoma refractory to immunotherapy. Preliminary results show partial or complete objective response rates in various tumor types.
The NADINA trial found that 59% of patients responded well to neoadjuvant immunotherapy before surgery, allowing them to forgo adjuvant treatment. This treatment approach also showed rapid effects, with 95% of patients remaining tumor-free after just six weeks.
Researchers have identified collagen features as valuable biomarkers for evaluating melanoma immunotherapy response. Single-fiber characteristics were found to be more sensitive to treatment-induced changes than bulk collagen features, offering insights into collagen remodeling over time.
Researchers found that GZ17-6.02 killed uveal melanoma cells by enhancing autophagy, inactivating key proteins, and reducing growth factors. The compound also interacted with doxorubicin and ERBB inhibitors to enhance tumor cell killing, suggesting potential as a single agent or combination therapy.
Researchers found that up to one in seven melanoma patients carry cancer susceptibility genes, suggesting family history may be a bigger risk factor than previously thought. This discovery supports the idea that there are risk factors beyond sun exposure that can influence an individual's chances of developing melanoma.
Researchers have discovered a liquid biopsy biomarker that can identify the effectiveness of treatment at an early stage, enabling more individualized treatment for melanoma patients. The biomarker, SHOX2 methylation in circulating cell-free DNA, was found to be elevated in 60% of melanoma patients and correlated with response to therapy.
A plant virus treatment, composed of cowpea mosaic virus nanoparticles, has shown remarkable success in improving survival rates and suppressing the growth of metastatic tumors across various cancer models. The treatment was effective even after surgical removal of tumors, indicating its potential to prevent metastasis.
Researchers have developed a new method to detect malignant melanoma using a microneedle patch that measures tyrosinase enzyme levels in the skin. This non-invasive technique has the potential to provide faster and more reliable results compared to traditional biopsies.
A Mayo Clinic study of 492,597 patients with melanoma found that Black men are more likely to be diagnosed at later stages and experience worse outcomes due to the disease. In contrast, Black female patients fared better, with a higher survival rate for stage 3 melanoma.
Researchers found a strong association between favorable survival outcomes and high populations of tissue-resident memory T cells in melanoma patients. The study identified 11 distinct gene signatures that correlate with T cell abundance and patient survival, suggesting a crucial role for T cells in immunomodulation.
Researchers at TUM have uncovered a mechanism by which tumor cells prevent the formation of immune responses, including cytotoxic T cells. This discovery provides rationales for new cancer immunotherapies and could enhance existing treatments.
Researchers at the University of Pittsburgh have discovered how to overcome resistance to conventional immunotherapies in metastatic uveal melanoma. They developed a clinical tool called Uveal Melanoma Immunogenic Score (UMIS) to predict patient response and improve treatment outcomes.
A study reveals that melanomas can 'break' parts of their BRAF gene through genomic deletions, creating alternative versions that resist targeted therapy. This discovery opens new avenues for developing effective treatments for patients with BRAF mutations.
A study of 12 patients with sinonasal mucosal melanoma found that brisk tumor-infiltrating lymphocytes associated with improved outcomes, while anti-PD-L1 therapy showed potential as a therapeutic strategy. Further research is needed to confirm these findings.
Researchers at the University of Cincinnati Cancer Center presented abstracts on new potential drugs and targets for treating various types of cancer. A study found that a brain-permeable drug called AM-101 sensitizes brain metastatic tumors to radiation, improving survival in preclinical animal models.
A second-generation melanoma vaccine has shown improved survival rates for male patients compared to female patients, particularly those who are younger and have earlier-stage cancer. The vaccine targets helper T cells to recognize melanoma proteins, leading to boosted patient survival and reduced cancer reoccurrences.
A mobile app using AI analyzes images of suspected skin lesions and provides guidance on whether they are melanoma or not. The app was tested in primary care and showed promising results, accurately diagnosing melanoma in all cases and determining harmless lesions with a high probability.
A new DNA origami platform, DoriVac, enables precise spacing of adjuvant molecules and a variety of antigens to enhance anti-tumor responses. The vaccine demonstrated enhanced efficacy in controlling tumor growth and prolonging survival in mice, synergizing with immune checkpoint inhibitors.
Research by Johns Hopkins Medicine suggests that increased stiffness in aging skin contributes to higher rates of melanoma metastasis by stimulating blood vessel growth and making them leaky. Treating older mice with drugs blocking ICAM1 prevented these changes, shrinking tumors and reducing metastasis.
Researchers at Johns Hopkins Medicine have reported promising results from a clinical trial testing a novel immunotherapy combination to target advanced, potentially lethal skin cancers in kidney transplant patients. Two out of six patients experienced complete tumor regression after adding a second checkpoint inhibitor to the regimen.
Researchers highlight difficulties in targeting metastatic tumors and propose two- and three-drug combinations to achieve effective tumor control. They also emphasize the need for simultaneous blocking of primary driving oncogene, evolving resistance mechanism, and secondary survival pathway.
A new study found that lockdown-induced delays in diagnosing melanoma led to over 100,000 years of life lost across Europe and £6.1 billion in costs, mainly due to loss of productivity. The research emphasizes the importance of considering unintended side effects in pandemic planning.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have identified the protein TYRP1 as a promising target for CAR T-cell therapy. The study demonstrates potent antitumor responses against cutaneous and rare melanoma types, offering new hope for treating these challenging-to-treat cancers.
Researchers found that tumors with preexisting immune cell networks were most primed to respond to adoptive T cell therapy, and patients whose tumors featured such networks responded best to treatment. The study provides a step towards identifying patients who are likely to benefit from personalized immunotherapies.
A new study found that FDG PET/CT imaging after just one week can predict treatment response in patients with advanced melanoma. The study identified metabolic changes in tumors that corresponded with treatment response and progression-free survival.
A new study estimates that up to 64.6% of melanomas diagnosed in white women and 49.7% in white men were overdiagnosed in 2018, leading to unnecessary treatments. The study found that the lifetime risk of being overdiagnosed with melanoma increased over the years.
Researchers have revealed CD4+ T cells can work effectively on their own to control melanoma, challenging conventional understanding. Harnessing their potential therapeutically holds great promise for improving current cancer immunotherapies.
In a new study published in Cancer Research, Moffitt researchers reveal how the antitumor activity of PTEN suppresses cancer-promoting activity through the AKT signaling pathway. PTEN's lipid phosphatase activity inhibits melanoma cell proliferation, invasion, and tumor growth.
Researchers at Moffitt Cancer Center analyzed the mechanisms of action of anti-PD-1/CTLA-4 and anti-PD-1/LAG-3 combination therapies, identifying specific subtypes of CD4 T cells that become activated. The study found differences in how these therapies affect CD4 T cells, leading to distinct anticancer effects.
Moffitt researchers found that HDAC8 inhibition of EP300 leads to melanoma cell metastasis to the brain, while no significant impact on other organs was observed. This study provides evidence for a new therapeutic target to inhibit brain metastasis.
Researchers discovered an alternative immune response involving NK and CD4+ T cells that can recognize and attack cancer cells when the usual recognition marker B2M is missing. This finding holds potential for developing more effective combination cancer immunotherapy treatments.
Scientists developed a synthetic melanin that accelerates wound healing and protects against sun damage. The cream also quiets the immune system, allowing for continuous repair and reducing inflammation.
Researchers at McGill University found that people who use sunscreen are more likely to develop skin cancer due to inadequate application or excessive sun exposure. Sunscreen is not the most effective way to protect against skin cancer, with clothing and avoidance being better options.
Researchers saw a major pathologic response in over half of surgical specimens from patients treated with neoadjuvant pembrolizumab. The treatment shrank over half of advanced melanomas, according to exploratory analyses presented at the European Society of Medical Oncology (ESMO) Congress 2023.
A study by Medical University of Vienna found that AI algorithms in smartphone applications perform well in diagnosing pigmented skin lesions, but are outperformed by doctors in treatment decisions. The 7-class algorithm showed equivalent diagnostic accuracy to experts, while the ISIC algorithm performed worse.
A new AI software has achieved a 100% detection rate for melanoma, significantly improving skin cancer detection accuracy. The software correctly identified 99.5% of all skin cancers and 92.5% of pre-cancerous lesions, with potential to reduce face-to-face consultations and enhance dermatology triage.
A recent study has found that non-melanoma skin cancer (NMSC) is causing a greater number of global deaths than melanoma. NMSC accounted for 78% of all skin cancer cases in 2020, resulting in over 63,700 deaths. The study highlights the need to implement effective strategies to reduce fatalities associated with all kinds of skin cancers.
A new cancer drug candidate has been found to restore the effectiveness of the immune system in fighting tumors, including melanoma, bladder cancer, leukemia, and colon cancer. The drug works by lowering a toxic compound called MTA, which impairs normal functioning of immune cells and blocks immunotherapies.
Researchers identified a circulating tumor DNA (ctDNA) biomarker that can predict disease recurrence and response to treatment in patients with BRAF-negative melanoma. The study found that measuring ctDNA levels and variants can help tailor therapy and improve patient outcomes.
Researchers from The University of Queensland and The Alfred hospital in Melbourne have identified gene variants associated with a higher risk of nodular melanoma. The study found that four genes with rare DNA variants were linked to the aggressive subtype, which accounts for most melanoma deaths.
Researchers at Dana-Farber and MD Anderson Cancer Center found that MTA buildup in tumor cells impairs T cell function. Depleting MTA with enzymes restores T cell activity, improving checkpoint inhibitor effectiveness in MTAP-deleted cancers.
Researchers discovered that fine-tuning mitochondrial energy production reduces melanoma tumor growth and enhances immune response in mice. The study reveals that manipulating mitochondrial electron transport increases expression of immune genes and makes tumor cells more visible to killer T cells.
UTHSC researchers are studying the role of balanced sex hormones in DNA repair in human melanocytes to determine if hormonal imbalances contribute to melanoma risk. The study aims to find novel prevention methods to decrease melanoma cases and potentially save lives.
Researchers at Moffitt will develop novel targeted alpha-particle therapies for uveal melanoma and other rare melanomas. The grant will fund projects aimed at advancing the therapy's efficacy and personalizing its treatment.
Researchers found decreased in situ and invasive melanoma diagnoses during the pandemic, which may reflect reduced skin cancer screening. Thick melanomas increased primarily due to a decrease in thin melanomas, rather than an absolute increase in thicker ones.
Researchers from Osaka University have identified a novel mechanism by which GREB1 Isoform4 is involved in pyrimidine synthesis and causes malignant melanoma. The study found that GREB1 Is4 promotes cancer cell proliferation and regulates pyrimidine metabolism, suggesting it as a new therapeutic target for melanoma.
A study by McGill University found that higher-income individuals and those with university education had increased rates of melanoma, while those earning less than $50,000 were more likely to work outdoors and experience occupational sun exposure. Men also had higher rates of melanoma and other skin cancers due to increased UV exposure.
Researchers discuss the essential role of macrophages in metastatic growth of lung colonies in melanoma, highlighting their importance in clearing challenges to tissue integrity and promoting growth-related processes. The authors emphasize the need for targeted therapies against macrophages to combat untreatable metastasis.
Researchers developed a minimally invasive microneedle platform capable of detecting protein biomarkers in response to immunotherapy against melanoma. The approach integrates with ultra-sensitive single-molecule detection and shows promise for effective drug screening and patient stratification.
Researchers found a combination of ipilimumab and nivolumab can extend progression-free survival and improve response rates in patients with resistant metastatic melanoma. The treatment showed a 37% improvement in progression-free survival compared to ipilimumab alone.
Researchers have developed an oncolytic virus that can 'warm up' cold tumors and improve immunotherapy outcomes. The virus was engineered to carry a gene encoding a TGF-β inhibitor, which greatly increased survival rates in mice with aggressive melanoma and other cancers.
Researchers found that ranolazine, a heart medication, slows down tumor progression and increases visibility of melanoma cells to the immune system. This combination could improve response rates for immunotherapies in patients with melanoma.
Research found that electrical activity between melanocytes and keratinocytes is critical to melanoma initiation, with GABA signaling playing a key role. The study's findings suggest that molecules carried by vesicles from melanocytes to keratinocytes may trigger the secretion of tumor-promoting proteins.
A new study from the University of South Australia reveals that golfers have a higher lifetime prevalence of skin cancer compared to the general population. The research highlights the importance of sun protection strategies for golfers, who spend extended periods in the sun.
Researchers developed a reinforcement learning model that incorporates human decision-making criteria to improve AI accuracy in skin cancer diagnoses. The study showed increased sensitivity for melanoma and basal cell carcinoma, leading to more accurate diagnoses and optimal treatment decisions.
A recent study found that increased skin cancer screening is not enough to address racial disparities in melanoma survival rates. Researchers suggest that educating physicians about presentation of melanoma in skin of color and making sure people have access to a dermatologist when they have a suspicious lesion could be more effective.
Researchers have identified podoplanin as a key protein driving the spread of mucosal melanoma, a rare and aggressive form of skin cancer. Eliminating this protein could lead to a potential treatment through antibody therapy, offering hope for patients with this devastating disease.